# ALMENAT SAS — FDA import alert red lists: firms subject to detention without physical examination

For ALMENAT SAS, import alert is 54-16; import alert name is "DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENT"; country is COLOMBIA; address is Av 39 Oeste No 10 Oeste , Cali, COLOMBIA; date published is 07/09/2026, verified against its source on 2026-08-06.

- **Firm:** ALMENAT SAS _(verified: appears in the quote below)_
- **Import alert:** 54-16 _(verified: appears in the quote below)_
- **Import alert name:** "DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENT" _(verified: appears in the quote below)_
- **Country:** COLOMBIA _(verified: appears in the quote below)_
- **Address:** Av 39 Oeste No 10 Oeste , Cali, COLOMBIA _(verified: appears in the quote below)_
- **Date published:** 07/09/2026 _(verified: appears in the quote below)_
- **Product code:** 54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human) | 65 P - - 02 Sildenafil Citrate (Regulator) | 66 V - - 99 Miscellaneous Patent Medicines, Etc. _(verified: appears in the quote below)_
- **Product:** biQ-FEL | biQ-FEL | biQ-FEL _(verified: appears in the quote below)_
- **FDA notes:** FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. | FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. | FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. _(verified: appears in the quote below)_

## What the source says

> ALMENAT SAS Date Published : 07/09/2026 Av 39 Oeste No 10 Oeste , Cali, COLOMBIA 54 - - - -- Vitamins/Minerals (Human/Animal); Proteins/Unconv Dietary Supp (Human) Date Published: 07/09/2026 Desc: biQ-FEL Notes: FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. 65 P - - 02 Sildenafil Citrate (Regulator) Date Published: 07/09/2026 Desc: biQ-FEL Notes: FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil. 66 V - - 99 Miscellaneous Patent Medicines, Etc. Date Published: 07/09/2026 Desc: biQ-FEL Notes: FDA�s Health Fraud Branch has determined that �biQ-FEL� appears to be an unapproved new drug for which introduction (or delivery for introduction) into interstate commerce would violate sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d), as discussed below. Furthermore, �biQ-FEL� appears to be a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352. Product contains undeclared sildenafil and tadalafil.

## Source

- https://www.accessdata.fda.gov/cms_ia/importalert_1141.html

Last verified: 2026-08-06. Review by: 2026-10-05.
Part of [FDA import alert red lists: firms subject to detention without physical examination](https://referencesource.org/fda-import-alert-red-list/).